ライフサイエンスコーパス: intranasal

1 ed-masked ITN treatments (sham extranasal or intranasal).

2 Intranasal 9cRA can facilitate the functional recovery a

3 um concentration (Tmax) in CSF was less upon intranasal administration (15min) compared to i.v. admin

4 eficient mice were infected with H1N1 PR8 by intranasal administration and course of influenza pneumo

5 tokine responses to allergens, while in vivo intranasal administration at very low doses led to local

6 These results suggest that intranasal administration could be a potential noninvasi

7 or, accumulates in cerebrospinal fluid after intranasal administration in macaques and humans and mod

8 Likewise, nCB intranasal administration induced emphysema in mouse lun

9 In both mice and ferrets, intranasal administration of a single dose of the eq/GA/

10 Therefore, this study compared intranasal administration of AgNPs versus soluble silver

11 Intranasal administration of allergen induced rises of a

12 Intranasal administration of Alternaria challenge reduce

13 lthy participants and studied the effects of intranasal administration of an arginine vasopressin 1A

14 Intranasal administration of CLH001 to BALB/c and NOD SC

15 Here we explored the effects of intranasal administration of exogenous recombinant human

16 More important, replenishment of Sema3E by intranasal administration of exogenous Sema3E protects m

17 mmation was subsequently induced by means of intranasal administration of house dust mite (HDM) extra

18 Moreover, intranasal administration of Il-1beta promoted clearance

19 Here, we treated mice with daily intranasal administration of insulin (1.75 U/day) for on

20 ese findings show a therapeutic potential of intranasal administration of insulin before surgery to r

21 The effect of intranasal administration of keratinocyte growth factor

22 Mice received unilateral intranasal administration of lipopolysaccharide (LPS) or

23 Intranasal administration of LTC4 to OVA-sensitized C57B

24 To investigate the effect of intranasal administration of major birch pollen allergen

25 ses of allergen-specific IgE levels, whereas intranasal administration of omalizumab did not enhance

26 We have shown that prophylactic intranasal administration of our lead fusion inhibitor e

27 Intranasal administration of oxytocin (vs placebo) incre

28 s who completed the trial showed that 6-week intranasal administration of oxytocin significantly redu

29 ent and bacterial clearance were restored by intranasal administration of recombinant CXCL5.

30 with vancomycin or streptomycin by repeated intranasal administration of Saccharopolyspora rectivirg

31 Intranasal administration of these peptides results in p

32 ceived focus in numerous studies associating intranasal administration of this peptide with various a

33 Whereas, intranasal administration of ziconotide in the form of i

34 Intranasal administration provides a non-invasive drug d

35 onotide to the cerebrospinal fluid (CSF) via intranasal administration.

36 Based on the fact that intranasal allergen application induces rises of systemi

37 re reduced only in piglets that had received intranasal alpha-GalCer.

38 show promise, each must be tested with both intranasal and intracranial administration to ensure the

39 ) was less pathogenic than wild-type VACV in intranasal and intradermal models of infection.

40 Both intranasal and intraperitoneal immunization with the non

41 ally, an experimental infection in pigs, via intranasal and intratracheal routes, was performed using

42 rate constant of ziconotide in CSF following intranasal and intravenous administration of ziconotide

43 ly susceptible to orthopoxvirus infection by intranasal and systemic routes.

44 neous (serum from mice intoxicated via oral, intranasal, and intravenous routes) samples.

45 To this aim, intranasal anti-Salmonella vaccination with an innovativ

46 ation of an intranasal corticosteroid and an intranasal antihistamine for initial treatment.

47 therapy with intranasal corticosteroid plus intranasal antihistamine is more effective than either a

48 using chlorhexidine gluconate washcloths and intranasal antiseptic ointment is effective in eradicati

49 Despite widespread reports that intranasal application of oxytocin has a variety of beha

50 Intranasal application of SseB-MB induced gut and system

51 nd increased airway responsiveness following intranasal aspergillus sensitization.

52 tion of nonliposomal phages 6 hours prior to intranasal bacterial challenge resulted in complete prot

53 However, the efficacy of intranasal bevacizumab has yet to be evaluated.

54 After intranasal bFGF-nanoliposomal treatment for 3 consecutiv

55 Intranasal bleomycin challenge exacerbated lung inflamma

56 ng HIV VLPs through an intramuscular priming-intranasal boosting immunization route.

57 We show that intranasal but not systemic administration of alpha-GalC

58 cy changed the severity of disease following intranasal C. burnetii challenge, suggesting that kerati

59 odels of infection: lower respiratory tract (intranasal challenge of 1 x 10(7) colony forming units [

60 Intranasal challenge of repeatedly GAS-inoculated mice p

61 Intranasal challenge with Bet v 1 induced increases in B

62 intraperitoneal ovalbumin-alum, followed by intranasal challenge with ovalbumin alone, to induce ada

63 This ensures effective protection against intranasal challenge with recombinant vaccinia virus enc

64 nd were rapidly expanded and activated after intranasal challenge with RV-A16.

65 HA/MF59 but not HA/PBS immunization against intranasal challenge with the homologous H1N1 (A/Califor

66 tibody access to the brain is observed after intranasal challenge with vesicular stomatitis virus.

67 R1(-/-) mice survived subsequent lethal VACV intranasal challenge, or defects of T cell activation or

68 ed in healthy subjects and those infected by intranasal challenge.

69 onchoalveolar lavage (BAL) fluid early after intranasal challenge.

70 h pollen were added to the allergen prior to intranasal challenge.

71 d bronchial inflammation were analyzed after intranasal challenges with allergen or PBS.

72 Repeated intranasal challenges with OVA caused AHR, eosinophilic

73 In follow-up studies in a murine model of intranasal Chlamydia trachomatis infection, we analogous

74 linician may recommend the combination of an intranasal corticosteroid and an intranasal antihistamin

75 an intranasal corticosteroid rather than an intranasal corticosteroid in combination with an oral an

76 persons aged 15 years or older, recommend an intranasal corticosteroid over a leukotriene receptor an

77 Combination therapy with intranasal corticosteroid plus intranasal antihistamine

78 der, routinely prescribe monotherapy with an intranasal corticosteroid rather than an intranasal cort

79 Intranasal corticosteroid use during pregnancy has incre

80 008, intranasal triamcinolone-exposed, other intranasal corticosteroid-exposed, and nonexposed women

81 Although the main symptomatic treatments are intranasal corticosteroids (INCS) (daily or on demand) a

82 sinusitis and nasal polyposis refractory to intranasal corticosteroids with 16 weeks of follow-up.

83 sinusitis and nasal polyposis refractory to intranasal corticosteroids, the addition of subcutaneous

84 ver residence time in the sinus cavity after intranasal delivery of AgNPs and AgNO3 to mice, and char

85 Intranasal delivery of nanoparticles in CF mice produces

86 Intranasal delivery of neuroprotective ST266 is a potent

87 bio-distribution and efficacy of noninvasive intranasal delivery of small interfering RNA (siRNA) aga

88 Intranasal delivery of the siRNA targeting Beclin1 signi

89 The findings are that (1) intravenous or intranasal delivery of TRPC3 channel lentiviral shRNAs o

90 eutic target in the olfactory bulb (i.e. via intranasal delivery) for controlling an imbalance in ene

91 ng to the selection of GSK2245035 (32) as an intranasal development candidate.

92 computer-generated schedule, to receive one intranasal dose of LAIV or placebo.

93 randomly allocated (2:1) to receive a single intranasal dose of masked trivalent live attenuated infl

94 quence (blocks of six) to receive either two intranasal doses (0.25 mL per nostril) of LAIV H5N2 (101

95 Younger subjects received either 1 or 2 intranasal doses of 10(7.0) fluorescent focus units of A

96 ent was confirmed in humans following single intranasal doses of 32 of >/=20 ng, and reproducible pha

97 l response was demonstrated following repeat intranasal dosing at weekly intervals.

98 These results indicate that the intranasal drug delivery allows for the direct delivery

99 Here we demonstrate that a single intranasal exposure to extract from the respiratory path

100 ed with wild-type (WT) littermates following intranasal exposure to HDM allergen.

101 Chronic intranasal exposure to the three different filtrates led

102 Intranasal exposure with receptor agonists induced the r

103 ed lung Th2 and eosinophilic responses after intranasal HDM challenge and normal IL-4 production, but

104 on and eosinophilic airway inflammation upon intranasal HDM challenge.

105 Asthma was induced in mice using intranasal house dust mite or aerosol ova-albumin challe

106 ion with ovalbumin (OVA) in combination with intranasal (i.n) exposure to OVA.

107 ategies were employed: intramuscular (i.m.), intranasal (i.n.) at a low dose and low volume, and i.n.

108 ional IgG responses in milk, while MVA prime/intranasal (i.n.) boost induced robust milk Env-specific

109 anchored form of EBOV glycoprotein GP, as an intranasal (i.n.) EBOV vaccine.

110 llergic reactivity following repeated weekly intranasal (i.n.) GSK2245035.

111 Intranasal (i.n.) infections preferentially generate Th1

112 Intranasal (i.n.) inoculation of mice represents an expe

113 trong protective immune responses through an intranasal (i.n.) route in mice.

114 Adult CD-1 mice infected by the intranasal (i.n.) route, showed that VEEV and WEEV enter

115 However, a four-week intranasal IFNbeta treatment of HIVgp120tg mice starting

116 Administration of intranasal IL-33 and TSLP was sufficient for mucous meta

117 ed in preparations from animals subjected to intranasal IL-33 pretreatment.

118 ffect on sublingually delivered antigen than intranasal immunisation.

119 that T cells, but not Abs, elicited through intranasal immunization can protect against a subsequent

120 t genital C. trachomatis infection following intranasal immunization is not dependent on Ab response

121 When used for mucosal intranasal immunization of Syrian hamsters, both SC-Ad a

122 ed allergic inflammation in the airways upon intranasal immunization with house dust mite, confirming

123 After intranasal immunization with inactive cholera toxin (CT)

124 In both species, a single dose of intranasal immunization with PIV5-vectored vaccines was

125 Importantly, intranasal immunization with PR8-amiR-93NP conferred cro

126 une correlates without causing disease after intranasal immunization with RSV F VLP in comparison to

127 ing protection without causing disease after intranasal immunization with virus-like particle vaccine

128 mice but were able to confer, upon a single intranasal immunization, complete protection against a l

129 ducing antigen-specific IgG production after intranasal immunization.

130 as obtained by combining intraperitoneal and intranasal immunization.

131 Here, we examined the effects of intranasal (IN) administration of extracellular vesicles

132 Intranasal (IN) administration, an alternative route for

133 chanism of focused ultrasound (FUS)-enhanced intranasal (IN) brain drug delivery and assess its feasi

134 d, we investigated in healthy humans whether intranasal (IN) insulin, which is known to effectively r

135 As OT is a peptide, delivery by the intranasal (IN) route is the preferred method in clinica

136 Intranasal infection of cotton rats (Sigmodon hispidus)

137 Following intranasal infection of neonatal C57BL/6 mice, we detect

138 senting cells (APCs) both prior to and after intranasal infection with A/California/04/09 (H1N1).

139 mation (ALI) was induced in mice followed by intranasal infection with A66.1 serotype 3 Streptococcus

140 Intranasal infection with attenuated RABV prolonged the

141 ated in the control of primary and secondary intranasal infection with B. melitensis Our analysis of

142 s used to deplete neutrophils in mice before intranasal infection with C. burnetii.

143 njection at varying doses, 24 hours prior to intranasal infection with H5N1 and H7N9 viruses for prop

144 7 in inducing humoral immune responses after intranasal infection with virus or immunization with inf

145 Furthermore, following intranasal infection with Y. pestis, A2AP-deficient mice

146 00 CFU from an otherwise lethal C. posadasii intranasal infection.

147 mory protective response against a secondary intranasal infection.

148 ance of C. burnetii from the lungs following intranasal infection.

149 Secondary intranasal infections are efficiently contained in the l

150 ecovered from 1 of 60 C57BL/6 mice following intranasal infections of up to 4,400 spores.

151 For an in vivo challenge study, prior Embp intranasal inoculation in chickens suppressed the viral

152 ion against H3N8 CIV challenge with a single intranasal inoculation in mice.

153 Intranasal inoculation in postnatal day 14 mice with VSV

154 Following direct intranasal inoculation of animals, the virus was detecte

155 5 mg/kg twice daily) prophylactically before intranasal inoculation of highly pathogenic H5N1 virus (

156 disease phenotype than wild-type mice after intranasal inoculation of RABV.

157 Pneumonia was induced by intranasal inoculation of S. pneumoniae.

158 ad and replication in the respiratory tract, intranasal inoculation resulted in confined spread to re

159 or during the passaging process, (ii) direct intranasal inoculation with the viral stock resulted in

160 Following a single intranasal inoculation, both animal species shed the vac

161 After intranasal inoculation, infectious virus was recovered o

162 e virus is large, as is the case with direct intranasal inoculation.

163 ogressive, uniformly fatal disease following intranasal inoculation.

164 The first group of mice were infected by intranasal instillation of bioluminescent strain 536 and

165 e model of experimental allergic asthma, the intranasal instillation of dust extracts from Amish but

166 After intranasal instillation of MS-WF, mice were infected wit

167 o HDM challenge than WT counterparts because intranasal instillation of the allergen induced markedly

168 in random order, study participants received intranasal insulin (60 IU) or placebo (8.7% sodium chlor

169 The next day, they were administered either intranasal insulin (60 IU) or placebo, following which t

170 Intranasal insulin also increased circulating cortisol l

171 Insulin spillover into circulation after intranasal insulin application was mimicked by an intrav

172 In conclusion, intranasal insulin does not affect HIS but rapidly impro

173 Fasting HIS index was not affected by intranasal insulin in CON and patients.

174 can lead to neuronal insulin resistance and intranasal insulin is being explored as a potential ther

175 In our study, intranasal insulin normalized the subjective and hormona

176 ssover trial, we investigated the effects of intranasal insulin on hepatic insulin sensitivity (HIS)

177 On two separate days, participants received intranasal insulin or placebo.

178 Similarly, in the second study, intranasal insulin reduced nicotine cravings over time (

179 As such, intranasal insulin should further be studied in a larger

180 In the original study, intranasal insulin significantly reduced morning nicotin

181 in reinstatement of drug use, we formulated intranasal insulin to evaluate its efficacy during acute

182 ain-liver crosstalk, but human studies using intranasal insulin to mimic central insulin delivery hav

183 Intranasal insulin transiently increased serum insulin l

184 odeficiency virus (FIV) infected cats, daily intranasal insulin treatment (20.0 IU/200 mul for 6 week

185 Moreover, intranasal insulin treatment improved neurobehavioral pe

186 In addition, intranasal insulin treatment of experimentally feline im

187 ulin and blood glucose levels observed after intranasal insulin.

188 A single intranasal/intratracheal inoculation of juvenile baboons

189 ackground: Whether vaccinating children with intranasal live attenuated influenza vaccine (LAIV) is m

190 umoral responses in tonsils and saliva after intranasal live attenuated influenza vaccine (LAIV) vacc

191 se and swelling elicited by Alternaria or by intranasal LTE4 GPR99 expression is detected on lung and

192 creased the numbers of CFU recovered from an intranasal mouse model of infection.

193 Intranasal NAD(+) treatment of prion-infected sick mice

194 , and 1 trial found that lower-concentration intranasal naloxone (2 mg/5 mL) was less effective than

195 imilar efficacy between higher-concentration intranasal naloxone (2 mg/mL) and intramuscular naloxone

196 Higher-concentration intranasal naloxone (2 mg/mL) seems to have efficacy sim

197 influenza virus A/Netherlands/602/09 by the intranasal or intratracheal route.

198 found no reduction in mouse viability after intranasal or intravenous inoculation of B. bacteriovoru

199 enetically attenuated LT adjuvant (LTK63) by intranasal or orogastric delivery, induced high antigen-

200 erature lends support to the hypothesis that intranasal OT consistently influences a wide spectrum of

201 Intranasal OT failed to reverse stress-induced social wi

202 high probability that most of the published intranasal OT findings do not represent true effects.

203 In contrast, intranasal OT increased social interaction in stressed m

204 Thus, the remarkable reports that intranasal OT influences a large number of human social

205 Intranasal OT largely reversed the effects of stress on

206 cle, we investigate to what extent the human intranasal OT literature lends support to the hypothesis

207 Our findings suggest a mechanism by which intranasal OT may bolster social motivation-one that cou

208 Our conclusion is that intranasal OT studies are generally underpowered and tha

209 Intranasal OT was administered to naive and stressed mic

210 Intranasal OT, which reduces social approach in female m

211 C57BL/6 mice were exposed to a first set of intranasal OVA challenge under SD or healthy sleep (HS)

212 The immune response to intranasal ovalbumin in mice was assessed with concomita

213 imed at targeting amygdala functioning using intranasal OXT administration.

214 Intranasal OXT is a leading candidate for treating socia

215 tested the efficacy and tolerability of 4-wk intranasal OXT treatment (24 International Units, twice

216 We assessed the effect of intranasal oxytocin (24 IU) administered to 29 healthy,

217 ng in heavy social male drinkers showed that intranasal oxytocin (24 IU) decreased neural cue-reactiv

218 -controlled crossover study with single-dose intranasal oxytocin (24 IU) in ten overweight or obese,

219 wenty-four normal weight volunteers received intranasal oxytocin (24 IU) or placebo in a double-blind

220 20; 85% accident victims) were randomized to intranasal oxytocin (8 days/40 IU twice daily) or placeb

221 cognition and behavior and the potential of intranasal oxytocin (IN-OT) to treat social impairment i

222 Both intranasal oxytocin administration and chemogenetic stim

223 Intranasal oxytocin administration early after trauma ma

224 Therefore, we investigated the effects of intranasal oxytocin administration early after trauma on

225 This study aimed to determine the effects of intranasal oxytocin administration on stress-induced alt

226 Intranasal oxytocin administration suppressed hypothalam

227 After intranasal oxytocin administration, participants showed

228 Effects of intranasal oxytocin also need proper dose-response studi

229 The wish to believe in the effectiveness of intranasal oxytocin appears to be widespread and needs t

230 response, corroborating research implicating intranasal oxytocin in the same processes.

231 eceptor (5-HT1AR) function is modified after intranasal oxytocin intake.

232 Acute intranasal oxytocin penetrates the brain and enhances ce

233 No effects of intranasal oxytocin were seen in reward circuits or on a

234 ata confirmed the utility of a pig model for intranasal particulate flu vaccine delivery platform to

235 ogenic for further development as a bivalent intranasal pediatric vaccine.

236 nicity and should be further developed as an intranasal pediatric vaccine.IMPORTANCE RSV and HPIV1 ar

237 isits (one with 40 IU INI and the other with intranasal placebo [INP] administration) 4 weeks apart.

238 bodies to phosphocholine, and survival after intranasal pneumococcal challenge.

239 Mouse mortality was monitored after intranasal pneumococcal challenge.

240 chlorhexidine washcloths and oral rinse and intranasal povidone-iodine decreased the SSI rate by mor

241 yet fail to confer protection, we found that intranasal priming engages both CD4(+) and CD8(+) T cell

242 In this study, we report that repeated intranasal rechallenges with only OVA Ag were sufficient

243 Administration of intranasal recombinant IFN beta (10(4) units) with fluti

244 Conversely, intranasal reconstitution of P to P(-/-) mice at the cha

245 (11/11) and all except one immunized by the intranasal route (5/6) survived.

246 andidates were tested in BALB/c mice via the intranasal route and induced both humoral and cell-media

247 9cRA or vehicle was given via an intranasal route daily starting from day 3.

248 II, and C57BL/6 mice vaccinated with NPs via intranasal route generated robust OVA-specific CD8(+) T

249 responses in mice when administered via the intranasal route in addition to provoking higher cross-r

250 ce when given by either the intramuscular or intranasal route of immunization and that the in vivo re

251 Pigs vaccinated twice with PLGA-KAg via intranasal route showed increased antigen specific lymph

252 ox lesions on tails of mice infected via the intranasal route with 10(5) PFU of recombinant IHD-J-Luc

253 Mice were immunized through the intranasal route with house dust mite (HDM) extract deri

254 nsport LENK exclusively to the brain via the intranasal route, with no peripheral exposure and nanopa

255 e serum antibodies by both intramuscular and intranasal routes of vaccination.

256 A bivalent intranasal RSV/HPIV3 vaccine candidate consisting of a c

257 uated in seronegative children as a bivalent intranasal RSV/HPIV3 vaccine, and it was well tolerated

258 Typhi, and survived lethal intranasal S. sonnei challenge.

259 However, after in vivo intranasal sensitization and challenge with HDM, DC-spec

260 e overall bioavailability of ziconotide from intranasal solution and gel formulations.

261 Intranasal spray application facilitates insulin deliver

262 nd FDC (FF 100/LEVO 200 mug), once daily via intranasal spray for 8 days.

263 he combination of LT receptor antagonist and intranasal steroids was used for the cases in which nasa

264 ibitors are stable at room temperature, this intranasal strategy is feasible even outside health care

265 s to investigate the effects of the Allergan Intranasal Tear Neurostimulator (ITN) on conjunctival go

266 concept, 6-week, open-label clinical trial, intranasal theophylline (an epithelial membrane transpor

267 esults regarding olfactory improvement using intranasal theophylline warrant confirmation in a random

268 Finally, naive TLR2(-/-) mice underwent intranasal transfer of bone marrow-derived wild-type mac

269 decreased the production of IL-17A, whereas intranasal transfer of fluid enriched with the pulmonary

270 Intranasal treatment of mice with DK128 conferred protec

271 Daily intranasal treatment of wild-type mice with C3a beginnin

272 ween-group differences in the use of topical intranasal treatment with bevacizumab vs estriol vs tran

273 mulates post-ischaemic neural plasticity and intranasal treatment with C3a receptor agonists is an at

274 Intranasal treatment with either of the variants increas

275 tween second- or third-trimester exposure to intranasal triamcinolone and the risk of SGA (OR, 1.06;

276 Maternal exposure to intranasal triamcinolone during pregnancy was not associ

277 Adjusting for potential confounders, use of intranasal triamcinolone during the first trimester of p

278 We aim to estimate the safety of intranasal triamcinolone use during pregnancy, which was

279 Pregnancy exposure to intranasal triamcinolone was not significantly associate

280 in Montreal, Quebec, Canada, from 1998-2008, intranasal triamcinolone-exposed, other intranasal corti

281 Overall, our results support the intranasal use of nanoliposomal bFGF as an efficient, no

282 In this study, we report the intranasal use of novel nanoliposomes for the brain deli

283 as a promising vaccine delivery platform for intranasal vaccination against Y. pestis and other infec

284 A single dose of intranasal vaccination induced potent innate, humoral, a

285 Intranasal vaccination of human volunteers with live inf

286 Notably, intranasal vaccination offers significantly better prote

287 ota in modulating the protective efficacy of intranasal vaccination through their effect on the IgA c

288 Importantly, intranasal vaccination with NPs co-loaded with F1-V and

289 We report here that intranasal vaccination with these peptides and the adjuv

290 riable N terminus of PspA (alpha1alpha2) for intranasal vaccination, which induced strong Th17 immuni

291 ic immunoglobulin receptor induced following intranasal vaccination.

292 ontribute to the local immune response after intranasal vaccination.

293 may develop nasal congestion as a result of intranasal vaccination.IMPORTANCE Despite decades of res

294 at protection is significantly improved with intranasal vaccine administration.

295 sent our characterization of these NPs as an intranasal vaccine platform using a model antigen and F1

296 ve attenuated influenza vaccine (LAIV) is an intranasal vaccine recently incorporated into the United

297 mutation in the P/C gene (C(Delta170)) as an intranasal vaccine vector to express the EBOV glycoprote

298 se results have significant implications for intranasal vaccines, which deliver antigen to mucosal-as

299 yte (CTL) immunity to airborne pathogens and intranasal vaccines.

300 ested as a prophylactic treatment in a mouse intranasal virus challenge study, and systemic administr